The most significant published evidence on retatrutide to date comes from a Phase 2 randomised controlled trial, the results of which were published in the New England Journal of Medicine in June 2023 (Jastreboff et al.)
Conversely, Wegovy, along with oral Wegovy, Zepbound, and Foundayo, are approved specifically for weight loss, offering tailor-made solutions suitable for telehealth and condition-focused prescriptions in Hamilton
Example 3 Comparative Spectroscopic Modeling Simulated EPR spectra compared with experimental data validate theoretical models
Too much fiber in a single meal creates gas, bloating, and discomfort that compounds the GI effects of the medication
Human safety data is limited, and individual results may vary